Spots Global Cancer Trial Database for Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Official Title: Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Study ID: NCT00872976
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution, New Hyde Park, New York, United States
Local Institution, Columbus, Ohio, United States
Local Institution, Nashville, Tennessee, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
